"COSCIENS Biopharma Inc. has announced its voluntary delisting from Nasdaq while retaining its listing on the TSX, a move seen as part of a strategic restructuring aimed at long-term value enhancement. The company's recent Q2 earnings report highlighted ongoing challenges, contributing to a cautious sentiment around its future performance, with risks including potential investor uncertainty following the delisting."